Resource utilization in patients with large B-cell lymphoma receiving tisagenlecleucel and axicabtagene ciloleucel

被引：1

作者：

Mian, Agrima ^{[1
]}

Wei, Wei ^{[2
]}

Hamilton, Betty K. ^{[3
]}

Winter, Allison M. ^{[3
]}

Khouri, Jack ^{[3
]}

Pohlman, Brad ^{[3
]}

Gerds, Aaron T. ^{[3
]}

Jagadeesh, Deepa ^{[3
]}

Anwer, Faiz ^{[3
]}

Kalaycio, Matt ^{[3
]}

Dean, Robert M. ^{[3
]}

Sobecks, Ronald ^{[3
]}

Caimi, Paolo F. ^{[3
]}

Hill, Brian T. ^{[3
]}

Majhail, Navneet S. ^{[4
]}

机构：

[1] Cleveland Clin, Dept Internal Med, Cleveland, OH USA

[2] Cleveland Clin, Dept Quantitat Hlth Sci, Cleveland, OH USA

[3] Cleveland Clin, Dept Hematol & Med Oncol, Blood & Marrow Transplant Program, Cleveland, OH USA

[4] Sarah Cannon, Nashville, TN 37203 USA

来源：

BONE MARROW TRANSPLANTATION | 2023年 / 58卷 / 05期

关键词：

TRANSPLANTATION; OUTCOMES; THERAPY;

D O I：

10.1038/s41409-023-01934-4

中图分类号：

Q6 [生物物理学];

学科分类号：

071011 ;

摘要：

引用

页码：590 / 593

页数：4

共 50 条

[21] EMA Review of Axicabtagene Ciloleucel (Yescarta) for the Treatment of Diffuse Large B-Cell Lymphoma
Papadouli, Irene
Mueller-Berghaus, Jan
Beuneu, Claire
Ali, Sahra
Hofner, Benjamin
Petavy, Frank
Tzogani, Kyriaki
Miermont, Anne
Norga, Koenraad
Kholmanskikh, Olga
Leest, Tim
Schuessler-Lenz, Martina
Salmonson, Tomas
Gisselbrecht, Christian
Garcia, Jordi Llinares
Pignatti, Francesco
ONCOLOGIST, 2020, 25 (10): : 894 - 902
[22] Tocilizumab Prophylaxis Following Axicabtagene Ciloleucel in Relapsed or Refractory Large B-Cell Lymphoma
Locke, Frederick L.
Neelapu, Sattva S.
Bartlett, Nancy L.
Lekakis, Lazaros J.
Jacobson, Caron A.
Braunschweig, Ira
Oluwole, Olalekan O.
Siddiqi, Tanya
Lin, Yi
Timmerman, John M.
Kersten, Marie Jose
Zheng, Yan
Zhang, Teresa
Nater, Jenny
Shen, Rhine
Miao, Harry
Kim, Jenny J.
Miklos, David B.
TRANSPLANTATION AND CELLULAR THERAPY, 2024, 30 (11): : 1065 - 1079
[23] Phase 2 study of axicabtagene ciloleucel in Japanese patients with relapsed or refractory large B-cell lymphoma
Koji Kato
Shinichi Makita
Hideki Goto
Junya Kanda
Nobuharu Fujii
Kazuyuki Shimada
Koichi Akashi
Koji Izutsu
Takanori Teshima
Natsuko Fukuda
Tokuhito Sumitani
Hiroyuki Sumi
Shinji Shimizu
Yasuyuki Kakurai
Kenji Yoshikawa
Kensei Tobinai
Noriko Usui
Kiyohiko Hatake
International Journal of Clinical Oncology, 2022, 27 : 213 - 223
[24] FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-cell Lymphoma
Bouchkouj, Najat
Kasamon, Yvette L.
de Claro, R. Angelo
George, Bindu
Lin, Xue
Lee, Shiowjen
Blumenthal, Gideon M.
Bryan, Wilson
McKee, Amy E.
Pazdur, Richard
CLINICAL CANCER RESEARCH, 2019, 25 (06) : 1702 - 1708
[25] Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma
Pinnix, Chelsea C.
Gunther, Jillian R.
Dabaja, Bouthaina S.
Strati, Paolo
Fang, Penny
Hawkins, Misha C.
Adkins, Sherry
Westin, Jason
Ahmed, Sairah
Fayad, Luis
Lee, Hun Ju
Nair, Ranjit
Steiner, Raphael E.
Iyer, Swaminathan P.
Rodriguez, M. Alma
Wang, Michael
Flowers, Christopher
Neelapu, Sattva S.
Nastoupil, Loretta J.
BLOOD ADVANCES, 2020, 4 (13) : 2871 - 2883
[26] Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S.
Locke, F. L.
Bartlett, N. L.
Lekakis, L. J.
Miklos, D. B.
Jacobson, C. A.
Braunschweig, I.
Oluwole, O. O.
Siddiqi, T.
Lin, Y.
Timmerman, J. M.
Stiff, P. J.
Friedberg, J. W.
Flinn, I. W.
Goy, A.
Hill, B. T.
Smith, M. R.
Deol, A.
Farooq, U.
McSweeney, P.
Munoz, J.
Avivi, I.
Castro, J. E.
Westin, J. R.
Chavez, J. C.
Ghobadi, A.
Komanduri, K. V.
Levy, R.
Jacobsen, E. D.
Witzig, T. E.
Reagan, P.
Bot, A.
Rossi, J.
Navale, L.
Jiang, Y.
Aycock, J.
Elias, M.
Chang, D.
Wiezorek, J.
Go, W. Y.
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (26): : 2531 - 2544
[27] Cytokines associated with prolonged Cytopenia after axicabtagene ciloleucel in patients with refractory large B-cell lymphoma
Strati, Paolo
Puebla-Osorio, Nahum
Han, Guangchun
Westin, Jason
Nastoupil, Loretta
Samaniego, Felipe
Fowler, Nathan
Fayad, Luis
Lee, Hun Ju
Flowers, Christopher
Srour, Samer
Watson, Grace
Wang, Linghua
Green, Michael
Neelapu, Sattva
CANCER RESEARCH, 2020, 80 (16)
[28] Phase 2 study of axicabtagene ciloleucel in Japanese patients with relapsed or refractory large B-cell lymphoma
Kato, Koji
Makita, Shinichi
Goto, Hideki
Kanda, Junya
Fujii, Nobuharu
Shimada, Kazuyuki
Akashi, Koichi
Izutsu, Koji
Teshima, Takanori
Fukuda, Natsuko
Sumitani, Tokuhito
Sumi, Hiroyuki
Shimizu, Shinji
Kakurai, Yasuyuki
Yoshikawa, Kenji
Tobinai, Kensei
Usui, Noriko
Hatake, Kiyohiko
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022, 27 (01) : 213 - 223
[29] Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma
Strati, Paolo
Nastoupil, Loretta J.
Westin, Jason
Fayad, Luis E.
Ahmed, Sairah
Fowler, Nathan H.
Hagemeister, Fredrick B.
Lee, Hun J.
Iyer, Swaminathan P.
Nair, Ranjit
Parmar, Simrit
Rodriguez, Maria A.
Samaniego, Felipe
Steiner, Raphael E.
Wang, Michael
Pinnix, Chelsea C.
Adkins, Sherry
Claussen, Catherine M.
Martinez, Charles S.
Hawkins, Misha C.
Johnson, Nicole A.
Singh, Prachee
Mistry, Haleigh E.
Horowitz, Sandra
George, Shirley
Feng, Lei
Kebriaei, Partow
Shpall, Elizabeth J.
Neelapu, Sattva S.
Tummala, Sudhakar
Chi, T. Linda
BLOOD ADVANCES, 2020, 4 (16) : 3943 - 3951
[30] Cost-Effectiveness Analysis of Axicabtagene Ciloleucel vs. Tisagenlecleucel for the Management of Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Spain
Bastos-Oreiro, Mariana
de las Heras, Ana
Presa, Maria
Casado, Miguel A.
Pardo, Carlos
Martin-Escudero, Victoria
Sureda, Anna
CANCERS, 2022, 14 (03)

← 1 2 3 4 5 →